Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising combo therapy shows hope for aggressive breast cancer

NCT ID NCT03036488

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding the drug pembrolizumab to standard chemotherapy helps people with triple negative breast cancer. Over 1,100 participants received either pembrolizumab or a placebo with chemo before surgery, then continued the study drug after surgery. The goal was to see if the combination leads to no cancer remaining at surgery and prevents the cancer from coming back.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,174 people

The number who actually took part.

Started

Mar 2017

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has newly diagnosed, locally advanced, centrally confirmed TNBC, as defined by the most recent American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. * Has previously untreated locally advanced non-metastatic (M0) TNBC defined as the following combined primary tumor (T) and regional lymph node (N) staging per current American Joint Committee of Cancer (AJCC) staging criteria for breast cancer as assessed by the investigator based on radiological and/or clinical assessment: * T1c, N1-N2 * T2, N0-N2 * T3, N0-N2 * T4a-d, N0-N2 * Provides a core needle biopsy consisting of at least 2 separate tumor cores from the primary tumor at screening to the central laboratory. * Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 10 days of treatment initiation. * Demonstrates adequate organ function. * Males and female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 12 months after the last dose of study treatment for participants who have received cyclophosphamide, and 6 months after the last dose of study treatment for participants who did not. Exclusion Criteria: * Has a history of invasive malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. * Has received prior chemotherapy, targeted therapy, and radiation therapy within the past 12 months. * Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed death - ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated antigen-4 \[CTLA-4\], OX-40, CD137 \[tumor necrosis factor receptor superfamily member 9 (TNFRSF9)\]) or has previously participated in a pembrolizumab (MK-3475) clinical study. * Is currently participating in or has participated in an interventional clinical study with an investigational compound or device within 4 weeks of the first dose of treatment in this current study. * Has received a live vaccine within 30 days of the first dose of study treatment. * Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). * Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (i.e., dosing exceeding 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. * Has a known history of Human Immunodeficiency Virus (HIV). * Has known active Hepatitis B or Hepatitis C. * Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis. * Has an active infection requiring systemic therapy. * Has significant cardiovascular disease, such as: history of myocardial infarction, acute coronary syndrome or coronary angioplasty/stenting/bypass grafting within the last 6 months OR congestive heart failure (CHF) New York Heart Association (NYHA) Class II-IV or history of CHF NYHA Class III or IV. * Is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the screening visit through 12 months after the last dose of study treatment for participants who have received cyclophosphamide, and for 6 months after the last dose of study treatment for participants who have not. * Has a known hypersensitivity to the components of the study treatment or its analogs. * Has a known history of active tuberculosis (TB, Bacillus Tuberculosis).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Triple negative breast neoplasms are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Triple negative breast neoplasms

Contacts and locations

Locations

  • Abdurrahman Yurtaslan Oncology Training and Research Hospital ( Site 1909)

    Ankara, 06200, Turkey (Türkiye)

  • Acibadem Altunizade Hastanesi ( Site 1900)

    Istanbul, 34662, Turkey (Türkiye)

  • Adana Acıbadem Hospital Department of Medical Oncology ( Site 1906)

    Adana, 01130, Turkey (Türkiye)

  • Aichi Cancer Center Hospital ( Site 2502)

    Nagoya, Aichi-ken, 464-8681, Japan

  • Akademiska Sjukhuset ( Site 1403)

    Uppsala, 751 85, Sweden

  • Amerikan Hospital Medical ( Site 1902)

    Istanbul, 34365, Turkey (Türkiye)

  • Antalya Memorial Hospital Department of Medical Oncology ( Site 1908)

    Antalya, 07020, Turkey (Türkiye)

  • Arizona Oncology Associates PC- HOPE ( Site 8001)

    Tucson, Arizona, 85711, United States

  • Arkhangelsk Clinical Oncological Dispensary ( Site 1810)

    Arkhangelsk, 163045, Russia

  • Asan Medical Center ( Site 2102)

    Seoul, 05505, South Korea

  • Assaf Harofeh MC ( Site 1605)

    Beer Yaakov-Zerifin, 7030001, Israel

  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia ( Site 1103)

    Brescia, 25100, Italy

  • Barts Cancer Institute ( Site 1500)

    London, EC1M 6BQ, United Kingdom

  • Baskent Unıversity Adana Kısla Hospital ( Site 1903)

    Adana, 01250, Turkey (Türkiye)

  • Bon Secours Cancer Institute Medical Oncology at St. Mary's ( Site 0033)

    Midlothian, Virginia, 23114, United States

  • Bon Secours Hospital ( Site 1551)

    Cork, T12 DV56, Ireland

  • Broome Oncology, LLC ( Site 8002)

    Johnson City, New York, 13790, United States

  • CHU Jean Minjoz ( Site 0917)

    Besançon, 25000, France

  • CHU de Quebec Universite Laval - Hopital du Saint-Sacrement ( Site 0104)

    Québec, Quebec, G1S 4L8, Canada

  • CHU de la Miletrie Poitiers ( Site 0913)

    Poitiers, 86021, France

  • CIUSSS de l'Estrie-CHUS ( Site 0102)

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Cabrini Health ( Site 2009)

    Malvern East, Victoria, 3145, Australia

  • Caritasklinik St. Theresia ( Site 1011)

    Saarbrücken, 66113, Germany

  • Cedars Sinai Medical Center ( Site 0091)

    Los Angeles, California, 90048, United States

  • Centre Francois Baclesse ( Site 0907)

    Caen, 14000, France

  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0106)

    Montreal, Quebec, H2X 0C1, Canada

  • Centre Jean Perrin ( Site 0903)

    Clermont-Ferrand, 63001, France

  • Centrum Onkologii Instytut im. Marii Sklodowskiej Curie ( Site 1719)

    Krakow, 31-115, Poland

  • Centrum Onkologii Instytut im. Marii Skłodowskiej Curie ( Site 1717)

    Gliwice, Silesian Voivodeship, 44-101, Poland

  • Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli ( Site 1700)

    Lublin, 20-090, Poland

  • Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1708)

    Bydgoszcz, 85-796, Poland

  • Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1712)

    Bydgoszcz, 85-796, Poland

  • Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1805)

    Chelyabinsk, 454087, Russia

  • Chiba Cancer Center ( Site 2519)

    Chiba, 260-8717, Japan

  • Christiana Hospital ( Site 0029)

    Newark, Delaware, 19713, United States

  • Clinique Victor Hugo ( Site 0901)

    Le Mans, 72015, France

  • Colchester General Hospital ( Site 1508)

    Colchester, Essex, CO4 5JL, United Kingdom

  • Complejo Hospitalario Universitario de Santiago ( Site 1308)

    Santiago de Compostela, 15706, Spain

  • Dolnoslaskie Centrum Onkologii. ( Site 1702)

    Wroclaw, 53-413, Poland

  • Ege University Medical Faculty Tulay Aktas Oncology Hospital ( Site 1905)

    Izmir, 35040, Turkey (Türkiye)

  • Frankston Hospital ( Site 2010)

    Franskton, 3199, Australia

  • Fundacao Champalimaud ( Site 2444)

    Lisbon, 1400-038, Portugal

  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto ( Site 0208)

    São José do Rio Preto, 15090-000, Brazil

  • GBU RO Regional Clinical Oncological Dispensary ( Site 1808)

    Ryazan, 390046, Russia

  • Goshen Center for Cancer Care ( Site 0010)

    Goshen, Indiana, 46526, United States

  • Gynaekologisches Zentrum ( Site 1004)

    Bonn, 53111, Germany

  • HELIOS Klinikum Berlin-Buch ( Site 1005)

    Berlin, 13125, Germany

  • Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 1912)

    Ankara, 06100, Turkey (Türkiye)

  • Hadassah Ein Karem - Sharett Institute of Oncology ( Site 1600)

    Jerusalem, 9112001, Israel

  • Hemato Oncologos S.A. ( Site 0400)

    Cali, 760001, Colombia

  • Henry Ford Hospital ( Site 0003)

    Detroit, Michigan, 48202, United States

  • Hiroshima City Hiroshima Citizens Hospital ( Site 2501)

    Hiroshima, 730-8518, Japan

  • Hopital Diaconesses Croix Saint Simon ( Site 0905)

    Paris, 75020, France

  • Hopital Saint Louis ( Site 0908)

    Paris, 75010, France

  • Hopital prive du Confluent ( Site 0902)

    Nantes, 44277, France

  • Hospital Araujo Jorge ( Site 0204)

    Goiânia, 74605-070, Brazil

  • Hospital Clinico Univ de Valencia ( Site 1313)

    Valencia, 46011, Spain

  • Hospital Erasto Gaertner ( Site 0207)

    Curitiba, 81520-060, Brazil

  • Hospital General Universitari Vall d Hebron ( Site 1301)

    Barcelona, 08035, Spain

  • Hospital Nossa Senhora da Conceicao ( Site 0203)

    Porto Alegre, Rio Grande do Sul, 91350-200, Brazil

  • Hospital Quiron de Madrid ( Site 1303)

    Pozuelo de Alarcón, Madrid, 28223, Spain

  • Hospital Sao Lucas da PUCRS ( Site 0200)

    Porto Alegre, 90610-900, Brazil

  • Hospital Universitario Ramon y Cajal ( Site 1300)

    Madrid, 28034, Spain

  • Hospital Universitario Reina Sofia ( Site 1304)

    Córdoba, 14004, Spain

  • Hospital Universitario San Ignacio ( Site 0401)

    Bogotá, 110231, Colombia

  • Hospital Universitario Virgen del Rocio ( Site 1314)

    Seville, 41013, Spain

  • Hospital de Santa Maria, E.P.E. ( Site 2445)

    Lisbon, 1600-190, Portugal

  • Hospital del Mar ( Site 1306)

    Barcelona, 08003, Spain

  • Houston Methodist Cancer Center ( Site 0013)

    Houston, Texas, 77030, United States

  • Hyogo College of Medicine Hospital ( Site 2506)

    Nishinomiya, Hyōgo, 663-8501, Japan

  • ICO L Hospitalet ( Site 1305)

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

  • ICRI ( Site 0072)

    Whittier, California, 90603, United States

  • Institut Claudius Regaud IUCT Oncopole ( Site 0914)

    Toulouse, 31059, France

  • Institut Curie ( Site 0909)

    Paris, 75005, France

  • Instituto De Cancerologia S.A. ( Site 0406)

    Medellín, 050024, Colombia

  • Instituto Nacional de Cancerologia [Bogota-Colombia] ( Site 0403)

    Bogotá, 110411, Colombia

  • Instituto Oncologico Baselga.Hospital Quiron. ( Site 1312)

    Barcelona, 08023, Spain

  • Instituto Portugues de Oncologia Do Porto Francisco Gentil E.P.E. ( Site 2446)

    Porto, 4200-072, Portugal

  • Instituto do Cancer de Sao Paulo - ICESP ( Site 0211)

    São Paulo, 01246-000, Brazil

  • Instituto do Cancer do Ceara ( Site 0205)

    Fortaleza, 60430-230, Brazil

  • Istituto Europeo di Oncologia ( Site 1106)

    Milan, 20141, Italy

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1102)

    Naples, 80131, Italy

  • Istituto Scientifico Romagnolo per Studio e Cura Tumori IRST ( Site 1101)

    Meldola, FC, 47014, Italy

  • Izmir Medical Park Hospital Department of Medical Oncology ( Site 1907)

    Izmir, 35575, Turkey (Türkiye)

  • Jewish General Hospital ( Site 0101)

    Montreal, Quebec, H3T 1E2, Canada

  • Kadlec Clinic Hematology and Oncology ( Site 0087)

    Kennewick, Washington, 99336, United States

  • Karolinska Universitetssjukhuset Solna ( Site 1404)

    Solna, 171 64, Sweden

  • Kindai University Hospital ( Site 2507)

    Sayama, Osaka, 589-8511, Japan

  • Kliniken Essen Mitte ( Site 1012)

    Essen, 45136, Germany

  • Klinikum der Universit. Muenchen ( Site 1002)

    München, 80337, Germany

  • Koo Foundation Sun Yat-Sen Cancer Center ( Site 2304)

    Taipei, 11259, Taiwan

  • Kumamoto University Hospital ( Site 2515)

    Kumamoto, 860-8556, Japan

  • Linkopings Universitetssjukhus ( Site 1402)

    Linköping, 581 85, Sweden

  • Linkou Chang Gung Memorial Hospital ( Site 2300)

    Taoyuan, 333, Taiwan

  • MacKay Memorial Hospital ( Site 2303)

    Taipei, 105, Taiwan

  • Magee - Women's Hospital ( Site 0011)

    Pittsburgh, Pennsylvania, 15213, United States

  • Maidstone Hospital ( Site 1511)

    Maidstone, ME16 9QQ, United Kingdom

  • Mazowiecki Szpital Onkologiczny ( Site 1713)

    Wieliszew, Masovian Voivodeship, 05-135, Poland

  • Medical Oncology Associates (Summit Cancer Centers) ( Site 0014)

    Spokane, Washington, 99208, United States

  • Memorial Sisli Hastanesi ( Site 1913)

    Istanbul, 34384, Turkey (Türkiye)

  • Minnesota Oncology Hematology, PA ( Site 8013)

    Minneapolis, Minnesota, 55404, United States

  • Moncrief Cancer Institute ( Site 0092)

    Fort Worth, Texas, 76104, United States

  • National Cancer Center Hospital ( Site 2500)

    Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East ( Site 2518)

    Kashiwa, Chiba, 277-8577, Japan

  • National Cancer Centre Singapore ( Site 2600)

    Singapore, 169610, Singapore

  • National Cheng Kung University Hospital ( Site 2305)

    Tainan, 704, Taiwan

  • National Hospital Organization Hokkaido Cancer Center ( Site 2512)

    Sapporo, Hokkaido, 003-0804, Japan

  • National Hospital Organization Osaka National Hospital ( Site 2505)

    Osaka, 540-0006, Japan

  • National Taiwan University Hospital ( Site 2301)

    Taipei, 100, Taiwan

  • New England Cancer Specialists ( Site 0005)

    Scarborough, Maine, 04074, United States

  • Norrlands Universitetssjukhus ( Site 1401)

    Umeå, 901 85, Sweden

  • North Shore University Health System ( Site 0081)

    Evanston, Illinois, 60201, United States

  • Northwest Cancer Specialists, P.C. ( Site 8008)

    Portland, Oregon, 97227, United States

  • Nottingham University Hospitals NHS Trust ( Site 1505)

    Nottingham, NG5 1PB, United Kingdom

  • Nyack Hospital Infusion Center ( Site 0059)

    Nyack, New York, 10960, United States

  • Oncologos del Occidente S.A. ( Site 0405)

    Pereira, Risaralda Department, 661002, Colombia

  • Oncology Hematology Care, Inc. ( Site 8011)

    Cincinnati, Ohio, 45242, United States

  • Oncology institute ( Site 1601)

    Beersheba, 8410101, Israel

  • Oncomedica S.A. ( Site 0404)

    Montería, Departamento de Córdoba, 230002, Colombia

  • Orchard Healthcare Research Inc. ( Site 0049)

    Skokie, Illinois, 60077, United States

  • Ospedale Civile di Macerata ( Site 1104)

    Province of Macerata, 62100, Italy

  • Ospedale San Luca, AZIENDA USL2 TOSCANA NORD OVEST ( Site 1105)

    Lucca, 55100, Italy

  • Ozel Medicana International Ankara Hastanesi ( Site 1915)

    Ankara, 06510, Turkey (Türkiye)

  • Pacific Cancer Care ( Site 0069)

    Monterey, California, 93940, United States

  • Parkland Health and Hospital System ( Site 0093)

    Dallas, Texas, 75235, United States

  • Peninsula Cancer Institute, LLC ( Site 0041)

    Newport News, Virginia, 23601, United States

  • Polyclinique Bordeaux Nord Aquitaine ( Site 0911)

    Bordeaux, 33077, France

  • Princess Margaret Cancer Centre ( Site 0103)

    Toronto, Ontario, M5G 2M9, Canada

  • Providence Portland Medical Center ( Site 0052)

    Portland, Oregon, 97213, United States

  • Rabin-Medical Center ( Site 1604)

    Petah Tikva, 4941492, Israel

  • Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1804)

    Ufa, 450054, Russia

  • Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1806)

    Kazan', 420029, Russia

  • Rhode Island Hospital ( Site 0060)

    Providence, Rhode Island, 02903, United States

  • Royal Adelaide Hospital ( Site 2008)

    Adelaide, South Australia, 5000, Australia

  • Royal Brisbane and Women s Hospital ( Site 2003)

    Herston, 4029, Australia

  • Royal Cornwall Hospitals NHS Trust ( Site 1504)

    Truro, TR1 3LJ, United Kingdom

  • Royal North Shore Hospital ( Site 2000)

    Sydney, New South Wales, 2065, Australia

  • Russian Oncological Research Center n.a. N.N.Blokhin of MoH ( Site 1801)

    Moscow, 115478, Russia

  • Rutgers Cancer Institute of New Jersey ( Site 0073)

    New Brunswick, New Jersey, 08903, United States

  • Saitama Cancer Center ( Site 2510)

    Kitaadachi-gun, Saitama, 362-0806, Japan

  • Saitama Medical University International Medical Center ( Site 2513)

    Hidaka, Saitama, 350-1298, Japan

  • Samsun Ondokuz Mayıs Universitesi Tıp Fakultesi Hastanesi ( Site 1910)

    Samsun, Atakum, 55280, Turkey (Türkiye)

  • Samsung Medical Center ( Site 2103)

    Seoul, 06351, South Korea

  • Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1803)

    Saint Petersburg, 197758, Russia

  • Seattle Cancer Care Alliance ( Site 0068)

    Seattle, Washington, 98109, United States

  • Seoul National University Hospital ( Site 2101)

    Seoul, 03080, South Korea

  • Severance Hospital Yonsei University Health System ( Site 2100)

    Seoul, 03722, South Korea

  • Sheba Medical Center ( Site 1602)

    Ramat Gan, 5265601, Israel

  • Shizuoka Cancer Center Hospital and Research Institute ( Site 2514)

    Sunto-gun, Shizuoka, 411-8777, Japan

  • Simmons Cancer Center ( Site 0094)

    Dallas, Texas, 75390-9015, United States

  • Social medical corporation Hakuaikai Sagara Hospital ( Site 2508)

    Kagoshima, 892-0833, Japan

  • Sourasky Medical Center ( Site 1603)

    Tel Aviv, 6423906, Israel

  • St George s Hospital ( Site 1516)

    London, SW17 0QT, United Kingdom

  • St John of God Subiaco Hospital ( Site 2006)

    Perth, 6008, Australia

  • St Vincents University Hospital ( Site 1550)

    Dublin, D04 T6F4, Ireland

  • St. Marianna University School of Medicine Hospital ( Site 2516)

    Kawasaki, Kanagawa, 216-8511, Japan

  • St.Luke's International Hospital ( Site 2511)

    Tokyo, 104-8560, Japan

  • Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 1701)

    Gdynia, 81-519, Poland

  • Taipei Veterans General Hospital ( Site 2302)

    Taipei, Beitou, 11217, Taiwan

  • Texas Oncology- Plano East ( Site 8010)

    Plano, Texas, 75075, United States

  • Texas Oncology-Austin Central ( Site 8005)

    Austin, Texas, 78731, United States

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center ( Site 8006)

    Dallas, Texas, 75246, United States

  • Texas Oncology-Memorial City ( Site 8003)

    Houston, Texas, 77024, United States

  • Texas Oncology-San Antonio Northeast ( Site 8012)

    San Antonio, Texas, 78217, United States

  • Texas Oncology-Tyler ( Site 8007)

    Tyler, Texas, 75702, United States

  • The Cancer Institute Hospital of JFCR ( Site 2509)

    Tokyo, 135-8550, Japan

  • The James Cook University Hospital ( Site 1515)

    Middlesbrough, TS4 3BW, United Kingdom

  • The Ottawa Hospital - Cancer Care ( Site 0100)

    Ottawa, Ontario, K1H 8L6, Canada

  • The University of Chicago Medical Center ( Site 0047)

    Chicago, Illinois, 60637-1447, United States

  • The West Clinic, P.C. ( Site 0078)

    Germantown, Tennessee, 38138, United States

  • Tokai University Hospital ( Site 2517)

    Isehara, Kanagawa, 259-1193, Japan

  • Tom Baker Cancer Centre ( Site 0105)

    Calgary, Alberta, T2N 4N2, Canada

  • Toranomon Hospital ( Site 2503)

    Tokyo, 105-8470, Japan

  • Trakya University Medical Faculty Balkan Oncology Hospital ( Site 1901)

    Edirne, 22030, Turkey (Türkiye)

  • TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0044)

    Cincinnati, Ohio, 45220, United States

  • UOPECCAN - Uniao Oeste Paranaense de Estudos e Combate ao Cancer ( Site 0206)

    Cascavel, 85806-300, Brazil

  • UT Southwestern Medical Center ( Site 0030)

    Dallas, Texas, 75390-9179, United States

  • Univ of Miami-Sylvester Comprehensive Cancer Center- Kendall satellite ( Site 0079)

    Miami, Florida, 33176, United States

  • Universidade de Caxias do Sul ( Site 0201)

    Caxias do Sul, 95070-560, Brazil

  • Universitaets-Frauenklinik Tuebingen ( Site 1003)

    Tübingen, 72076, Germany

  • Universitaetsklinik und Poliklinik Halle/Saale ( Site 1008)

    Halle, 06120, Germany

  • Universitaetsklinikum Erlangen ( Site 1001)

    Erlangen, 91054, Germany

  • Universitaetsklinikum Hamburg-Eppendorf ( Site 1007)

    Hamburg, 20246, Germany

  • University of Colorado Cancer Center ( Site 0021)

    Aurora, Colorado, 80045, United States

  • University of Iowa Hospital and Clinics ( Site 0038)

    Iowa City, Iowa, 52242, United States

  • University of Virginia ( Site 0022)

    Charlottesville, Virginia, 22903, United States

  • Virginia Cancer Specialists, PC ( Site 8009)

    Fairfax, Virginia, 22031, United States

  • Virginia G. Piper Cancer Center Pharmacy - Scottsdale Healthcare ( Site 0089)

    Scottsdale, Arizona, 85268, United States

  • Virginia Oncology Associates ( Site 8000)

    Norfolk, Virginia, 23502, United States

  • Westmead Hospital ( Site 2002)

    Sydney, New South Wales, 2145, Australia

  • YVMH dba Vrigina Mason Memorial/North Star Lodge Cancer Center ( Site 8004)

    Yakima, Washington, 98902, United States

  • Yale University School of Medicine ( Site 0054)

    New Haven, Connecticut, 06510, United States

  • İstanbul University Cerrahpaşa Medical Faculty ( Site 1904)

    Istanbul, 34098, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.